tirzepatide weight loss nejm SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants Tirzepatide dosage chart for weight

The Labeled Population Is the Starting Point Wegovy injection is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition

It may be considered in situations when: The body requires extra support in regulating appetite, digestion, or blood sugar levels, beyond what current measures provide Other first-line treatments have caused adverse effects or are not appropriate for the individual There is a higher BMI along with associated conditions (such as raised blood pressure or abnormal lipid levels) that indicate further intervention may be beneficial Tirzepatide is typically prescribed as part of a broader approach that includes dietary adjustments and regular physical activity

Since mitochondria are critically involved in calcium ion transport and zinc participates in mitochondrial ETC and ATP synthesis, an imbalance in calcium and zinc ions can substantially damage mitochondria

Some people also report rashes, muscle pains, and diarrhea